Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review.

[1]  M. Legato.  Principles of gender-specific medicine , 2010 .

[2]  S. Marcus,et al.  Depression in childbearing women: when depression complicates pregnancy. , 2009, Primary care.

[3]  Yung-Tian A Gau,et al.  Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. , 2009, Journal of affective disorders.

[4]  S. Marcus.  Depression during pregnancy: rates, risks and consequences--Motherisk Update 2008. , 2009, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[5]  T. Kinoshita,et al.  Predictors of response to sertraline in patients with major depression , 2008, Human psychopharmacology.

[6]  Z. Fišar,et al.  Platelet serotonin uptake in drug-naïve depressive patients before and after treatment with citalopram , 2008, Psychiatry Research.

[7]  G. Koren,et al.  Antenatal Use of Selective Serotonin-Reuptake Inhibitors and QT Interval Prolongation in Newborns , 2008, Pediatrics.

[8]  B. Källén,et al.  Maternal use of selective serotonin re‐uptake inhibitors and persistent pulmonary hypertension of the newborn , 2008, Pharmacoepidemiology and drug safety.

[9]  T. Einarson,et al.  Does paroxetine cause cardiac malformations? , 2008, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[10]  C. Eap,et al.  CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response , 2008, Therapeutic drug monitoring.

[11]  T. Einarson,et al.  Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. , 2008, The American journal of psychiatry.

[12]  A. Bérard,et al.  Duration of antidepressant use during pregnancy and risk of major congenital malformations , 2008, British Journal of Psychiatry.

[13]  D. Juurlink,et al.  The Risk of Postpartum Hemorrhage With Selective Serotonin Reuptake Inhibitors and Other Antidepressants , 2008, Journal of clinical psychopharmacology.

[14]  L. Schneider,et al.  Sex, Race, and Smoking Impact Olanzapine Exposure , 2008, Journal of clinical pharmacology.

[15]  M. Bonati,et al.  Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study , 2007, BJOG : an international journal of obstetrics and gynaecology.

[16]  M. Reis,et al.  Therapeutic Drug Monitoring of Escitalopram in an Outpatient Setting , 2007, Therapeutic drug monitoring.

[17]  B. Källén,et al.  Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants , 2007, Journal of clinical psychopharmacology.

[18]  R. Platt,et al.  Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy , 2007, Pharmacoepidemiology and drug safety.

[19]  S. Ephross,et al.  Paroxetine in the first trimester and the prevalence of congenital malformations , 2007, Pharmacoepidemiology and drug safety.

[20]  J. Hennen,et al.  Birth outcomes following prenatal exposure to antidepressants. , 2007, The Journal of clinical psychiatry.

[21]  J. Mintz,et al.  Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. , 2007, The American journal of psychiatry.

[22]  S. Hernández-Díaz,et al.  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. , 2007, The New England journal of medicine.

[23]  B. Haight,et al.  Bupropion in pregnancy and the prevalence of congenital malformations , 2007, Pharmacoepidemiology and drug safety.

[24]  T. Einarson,et al.  Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. , 2007, Clinical therapeutics.

[25]  Lucie Blais,et al.  First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. , 2007, Birth defects research. Part B, Developmental and reproductive toxicology.

[26]  Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. , 2007, The Journal of clinical psychiatry.

[27]  A. Carceller,et al.  Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates , 2007, Pediatrics.

[28]  R. Ehrenkranz.  Neonatal Outcomes After Prenatal Exposure to Selective Serotonin Reuptake Inhibitor Antidepressants and Maternal Depression Using Population-Based Linked Health Data , 2007 .

[29]  B. Pollock,et al.  Population pharmacokinetics in geriatric psychiatry. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[30]  M. Flores-Ramos,et al.  Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. , 2006, Journal of affective disorders.

[31]  M. Fava,et al.  Predictors of relapse in a prospective study of fluoxetine treatment of major depression. , 2006, The American journal of psychiatry.

[32]  T. Einarson,et al.  Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. , 2006, The Journal of clinical psychiatry.

[33]  M. Fava,et al.  Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. , 2006, The Journal of clinical psychiatry.

[34]  G. Nucci,et al.  Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents with Major Depressive Disorder or Obsessive–Compulsive Disorder , 2006, Neuropsychopharmacology.

[35]  D. Stewart,et al.  Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials. , 2006, The Journal of clinical psychiatry.

[36]  B. Pollock,et al.  Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. , 2006, British journal of clinical pharmacology.

[37]  J. Alderman,et al.  Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. , 2006, Journal of child and adolescent psychopharmacology.

[38]  M. Kölch,et al.  Antidepressant use in children and adolescents in Germany. , 2006, Journal of child and adolescent psychopharmacology.

[39]  S. Hernández-Díaz,et al.  Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn , 2006, The New England journal of medicine.

[40]  J. Ferguson,et al.  Pharmacokinetics of Fluoxetine in Elderly Men and Women , 2006, Gerontology.

[41]  A. Portolés,et al.  Comparative bioavailability/ bioequivalence of two different sertraline formulations: a randomised, 2-period x 2-sequence, crossover clinical trial in healthy volunteers. , 2011, Arzneimittel-Forschung.

[42]  Megan Williams,et al.  Paroxetine (Paxil) and congenital malformations , 2005, Canadian Medical Association Journal.

[43]  M. Thase,et al.  Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. , 2005, Journal of women's health.

[44]  J. Ahlner,et al.  Inter- and Intraindividual Pharmacokinetic Variations of Mirtazapine and Its N-Demethyl Metabolite in Patients Treated for Major Depressive Disorder: A 6-Month Therapeutic Drug Monitoring Study , 2005, Therapeutic drug monitoring.

[45]  C. Eap,et al.  Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[46]  H. Higuchi,et al.  Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. , 2005, Psychiatry and clinical neurosciences.

[47]  G. Koren,et al.  Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. , 2005, American journal of obstetrics and gynecology.

[48]  Andrew Bate,et al.  Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis , 2005, The Lancet.

[49]  C. Mallinckrodt,et al.  Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features , 2005, BMC psychiatry.

[50]  L. Bertilsson,et al.  Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype , 1996, Psychopharmacology.

[51]  C. Kuhn,et al.  Menstrual cycle effects on caffeine elimination in the human female , 2005, European Journal of Clinical Pharmacology.

[52]  B. Pollock,et al.  Gender and Antidepressants , 2004 .

[53]  D. Kupfer,et al.  Utility of Sparse Concentration Sampling for Citalopram in Elderly Clinical Trial Subjects , 2004, Journal of clinical pharmacology.

[54]  Saima Akhter,et al.  Gender based response to fluoxetine hydrochloride medication in endogenous depression. , 2004, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[55]  A. Conca,et al.  Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? , 2004, International journal of clinical pharmacology and therapeutics.

[56]  E. Baca,et al.  Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[57]  E. Steyerberg,et al.  The Danish University Antidepressant Group: Are gender differences important for the clinical effects of antidepressants? , 2003 .

[58]  M. Reis,et al.  Therapeutic Drug Monitoring of Racemic Citalopram: A 5-Year Experience in Sweden, 1992–1997 , 2003, Therapeutic drug monitoring.

[59]  B. Pollock,et al.  A Preliminary Study of the Effect of Fluoxetine Treatment on the 2:16-&agr;-Hydroxyestrone Ratio in Young Women , 2003, Therapeutic drug monitoring.

[60]  B. Pollock,et al.  Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. , 2003, The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia.

[61]  J. Ahlner,et al.  Serum Levels of Citalopram and Its Main Metabolites in Adolescent Patients Treated in a Naturalistic Clinical Setting , 2002, Journal of clinical psychopharmacology.

[62]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[63]  L. Balant,et al.  Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability , 2002, European Journal of Clinical Pharmacology.

[64]  R. van Reekum,et al.  Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease , 2002, International journal of geriatric psychiatry.

[65]  E. Smeraldi,et al.  Are gender differences in antiobsessional response related to different clomipramine metabolism? , 2002, Journal of clinical psychopharmacology.

[66]  E. Vittinghoff,et al.  Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. , 2002, JAMA.

[67]  M. Thase,et al.  Gender-specific differences in depression and treatment response. , 2002, Psychopharmacology bulletin.

[68]  S. Bellino,et al.  Discontinuation Syndrome in Dysthymic Patients Treated with Selective Serotonin Reuptake Inhibitors , 2002, CNS drugs.

[69]  Hartmut Derendorf,et al.  How Important Are Gender Differences in Pharmacokinetics? , 2002, Clinical pharmacokinetics.

[70]  N. Turhan,et al.  Intermittent versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorders. , 2001, International journal of fertility and women's medicine.

[71]  H. Berkel,et al.  Single‐Dose Pharmacokinetics of Bupropion in Adolescents: Effects of Smoking Status and Gender , 2001, Journal of clinical pharmacology.

[72]  F. Martényi,et al.  Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile , 2001, European Neuropsychopharmacology.

[73]  L. Kahn,et al.  Role of Estrogen in the Aetiology and Treatment of Mood Disorders , 2001, CNS drugs.

[74]  E. Frank,et al.  Risk-benefit decision making for treatment of depression during pregnancy. , 2000, The American journal of psychiatry.

[75]  M. Thase,et al.  Gender differences in treatment response to sertraline versus imipramine in chronic depression. , 2000, The American journal of psychiatry.

[76]  C J Timmer,et al.  Clinical Pharmacokinetics of Mirtazapine , 2000, Clinical pharmacokinetics.

[77]  M. Cotterchio,et al.  Antidepressant medication use and breast cancer risk. , 2000, American journal of epidemiology.

[78]  S. Shapiro,et al.  Risk of Breast Cancer According to Use of Antidepressants, Phenothizaines, and Anthistamines , 1999 .

[79]  E. Frank,et al.  Pharmacologic treatment of depression during pregnancy. , 1999, JAMA.

[80]  M. Folan,et al.  Inhibition of Caffeine Metabolism by Estrogen Replacement Therapy in Postmenopausal Women , 1999, Journal of clinical pharmacology.

[81]  B. Källén,et al.  Delivery outcome after the use of antidepressants in early pregnancy , 1999, European Journal of Clinical Pharmacology.

[82]  E. Mundo,et al.  Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? , 1999, Biological Psychiatry.

[83]  S. Faraone,et al.  Desipramine clearance in children and adolescents: absence of effect of development and gender. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[84]  D. Stewart.  Are There Special Considerations in the Prescription of Serotonin Reuptake Inhibitors for Women? , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[85]  E. Eriksson,et al.  Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? , 1998, Journal of clinical psychopharmacology.

[86]  H. Wetzel,et al.  Nonlinear pharmacokinetics of fluvoxamine and gender differences. , 1998, Therapeutic drug monitoring.

[87]  K. Ormond,et al.  Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. , 1998, JAMA.

[88]  A. Kashuba,et al.  Physiological Changes During the Menstrual Cycle and Their Effects on the Pharmacokinetics and Pharmacodynamics of Drugs , 1998, Clinical pharmacokinetics.

[89]  R. Howard,et al.  Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. , 1995, The Journal of clinical psychiatry.

[90]  R. Hirschfeld,et al.  Assessment and treatment of suicidal patients. , 1997, The New England journal of medicine.

[91]  J. Smoller,et al.  Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. , 1997, The Journal of clinical psychiatry.

[92]  G. Koren,et al.  Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. , 1997, Journal of psychiatry & neuroscience : JPN.

[93]  U. Halbreich.  Role of estrogen in postmenopausal depression , 1997, Neurology.

[94]  S. Preskorn,et al.  Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors , 1997, Clinical Pharmacokinetics.

[95]  M. Steiner,et al.  Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. , 1997, Psychopharmacology bulletin.

[96]  L. Tremaine,et al.  Pharmacokinetics of Sertraline and its N-Demethyl Metabolite in Elderly and Young Male and Female Volunteers , 1997, Clinical pharmacokinetics.

[97]  C. Timmer,et al.  Pharmacokinetics of Mirtazapine from Orally Administered Tablets: Influence of Gender, Age and Treatment Regimen , 1996 .

[98]  R. Barbhaiya,et al.  A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. , 1996, Journal of clinical psychopharmacology.

[99]  E. Schuetz,et al.  Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. , 1995, The Journal of pharmacology and experimental therapeutics.

[100]  B. Pollock,et al.  Pharmacokinetics of Single‐ and Multiple‐Dose Bupropion in Elderly Patients with Depression , 1995, Journal of clinical pharmacology.

[101]  N. Rojansky,et al.  Estrogen augments serotonergic activity in postmenopausal women , 1995, Biological Psychiatry.

[102]  J. Kelsoe,et al.  Gender differences in outpatient research subjects with affective disorders: a comparison of descriptive variables. , 1995, The Journal of clinical psychiatry.

[103]  C. Naranjo,et al.  Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. , 1995, Addiction.

[104]  D. Klein,et al.  Columbia Atypical Depression , 1993, British Journal of Psychiatry.

[105]  E. Eriksson,et al.  Clomipramine Administered during the Luteal Phase Reduces the Symptoms of Premenstrual Syndrome: A Placebo-Controlled Trial , 1993, Neuropsychopharmacology.

[106]  Bennett Jc.  Inclusion of women in clinical trials--policies for population subgroups. , 1993 .

[107]  D A Kessler,et al.  Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. , 1993, The New England journal of medicine.

[108]  E. Vesell,et al.  Underrepresentation of women in clinical drug trials , 1993, Clinical pharmacology and therapeutics.

[109]  J. Ford,et al.  Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease , 1993, Clinical pharmacology and therapeutics.

[110]  G. Koren,et al.  Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac) , 1993, JAMA.

[111]  F. Goodwin,et al.  The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. , 1993, Archives of general psychiatry.

[112]  J. Bennett,et al.  Inclusion of women in clinical trials--policies for population subgroups. , 1993, The New England journal of medicine.

[113]  K. Wisner,et al.  Tricyclic dose requirements across pregnancy. , 1993, The American journal of psychiatry.

[114]  I. Gotlib,et al.  Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. , 1989, Journal of consulting and clinical psychology.

[115]  A. Wald,et al.  Influence of gender and menopause on gastric emptying and motility. , 1989, Gastroenterology.

[116]  D. Greenblatt,et al.  Trazodone kinetics: Effect of age, gender, and obesity , 1987, Clinical pharmacology and therapeutics.

[117]  J. Davidson,et al.  Forms of atypical depression and their response to antidepressant drugs , 1986, Psychiatry Research.

[118]  J. Hamilton,et al.  Sex-related differences in clinical drug response: implications for women's health. , 1983, Journal of the American Medical Women's Association.

[119]  D. Greenblatt,et al.  Physiologic Changes in Old Age: Relation to Altered Drug Disposition , 1982, Journal of the American Geriatrics Society.

[120]  A H Neims,et al.  The disposition of caffeine during and after pregnancy. , 1981, Seminars in perinatology.

[121]  J. Gavaler,et al.  Gastrointestinal transit the effect of the menstrual cycle , 1981 .

[122]  J S Harmatz,et al.  Oxazepam kinetics: effects of age and sex. , 1980, The Journal of pharmacology and experimental therapeutics.

[123]  C. Naranjo,et al.  Sex-related variations in the frequency and characteristics of adverse drug reactions. , 1980, International journal of clinical pharmacology, therapy, and toxicology.

[124]  A. Raskin.  AGE‐SEX DIFFERENCES IN RESPONSE TO ANTIDEPRESSANT DRUGS , 1974, The Journal of nervous and mental disease.

[125]  J. Kirsner,et al.  BASAL AND HISTALOG-STIMULATED GASTRIC SECRETION IN CONTROL SUBJECTS AND IN PATIENTS WITH PEPTIC ULCER OR GASTRIC CANCER. , 1963, Gastroenterology.